1. Guidance for industry Q3B(R2) impurities in new drug products,2006
2. M7 assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk;U.S. Department of Health and Human Services,2015
3. ICH (R1) validation of analytical procedures: text and methodology,2005
4. ICH (Q3A) impurities in new drug substances,2006
5. Two-dimensional HPLC in pharmaceutical analysis;Zhang;Am. Pharm. Rev.,2013